Mentice secures $2.4M in several orders from one Top 20 Global MedTech Company in Interventional Cardiology, focused on Structural Heart Disease

“These major orders from a long-term innovative customer underscore the strength of our customer relationships and the trust leading medical technology companies place in Mentice,” said Frans Venker, CEO of Mentice. “We remain committed to delivering solutions that help our customers accelerate training, improve clinical outcomes, and bring new therapies to physicians and patients around the world. This order expands our simulation into augmented reality to provide not only haptic feedback but also contextual three-dimensional awareness and training.”

These orders continue to underscore the expanding role of simulation in elevating procedural proficiency and patient outcomes in complex cardiovascular interventions. As the healthcare industry prioritizes more immersive, high-fidelity educational experiences, Mentice remains a trusted partner in enabling such progress through its clinically validated solutions.

This strategic order will be recognized under the Mentice Medical Device Industry division and the revenue will be recognized over the coming quarters, contributing meaningfully to the company’s growth trajectory and solidifying its footprint within the interventional cardiology training ecosystem.

Mentice continues to deliver on its mission to empower healthcare providers and MedTech innovators with evidence-based, high-impact simulation platforms that accelerate learning, improve outcomes, and ensure consistent procedural excellence.

Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html